Research programme: skin disorder therapeutic - Trophea
Latest Information Update: 31 Jan 2017
At a glance
- Originator Trophea
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 30 Jan 2017 Preclinical trials in Skin disorders in Sweden (Topical)